Compare Cassava Sciences Inc (FLNA) vs Veritone Inc (VERI) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Veritone (VERI) trades at $1.005, down 6.07% in the last session, reflecting significant investor concern. The stock shows a bearish technical signal with moving averages indicating strong selling pressure. Fundamentally, the company reported a net loss of $111.73M on $92.19M revenue for 2025, with a negative net income margin of -123.76%, though it maintains a high gross margin of 68.52%. Recent news is dominated by multiple class-action lawsuits alleging revenue overstatements, with key deadlines approaching in July 2026.

The outlook is highly challenged. While analyst consensus shows a split between Buy and Hold ratings, severe financial losses, negative cash flow from operations, and ongoing litigation create substantial downside risk. The company's ability to achieve profitability and manage legal liabilities remains the critical factor for any potential recovery in shareholder value.